BCA
RYTM icon

Berman Capital Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Berman Capital Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42
Closed – – 2202
2021
Q2 		$0 Hold
42
– – ﹤0.01% 2018
2021
Q1 		$0 Sell
42
-15
-26% -$435 ﹤0.01% 1879
2020
Q4 		$1K Hold
57
– – ﹤0.01% 1580
2020
Q3 		$1K Sell
57
-121
-68% -$2.77K ﹤0.01% 1506
2020
Q2 		$3K Buy
+178
New +$3.47K ﹤0.01% 1174

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's RYTM Position: Q3 2021 in Review

Berman Capital Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2021, closing a stake of 42 shares.

Berman Capital Advisors first reported a position in RYTM in Q2 2020 and held it in 5 quarters. The position peaked at $3K in Q2 2020. 97 funds tracked by Wall St. Rank hold RYTM as of Q3 2021.

  • Berman Capital Advisors reported no remaining Rhythm Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 42 Rhythm Pharmaceuticals shares in Q3 2021.
  • Berman Capital Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Berman Capital Advisors's Rhythm Pharmaceuticals position peaked at $3K in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.